Cedars Sinai Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI 38th Annual Case Review with the Experts 2026

Description

Include: 4 videos + 53 pdf, size: 6.07 GB

Target Audience: cardiologists and radiologists

Information:

Friday, January 23, 2026, 7:30 AM – Sunday, January 25, 2026, 2:55 PM PT, Cedars-Sinai Harvey Morse Conference Center, Los Angeles, CA

Target Audience

A major national healthcare imperative for noninvasive imaging is for the tests to provide value. Nuclear cardiology and cardiac CT studies provide powerful tools for diagnosis, risk assessment, and guiding management of selected patients with known or suspected cardiac disease. In the current environment, imaging must address the combined considerations of improving outcomes and containing costs. To this end, advanced cardiac imaging studies must be ordered on the right patients and optimally performed, interpreted, reported, and acted upon by physicians and allied health professionals. Additionally, effective methods to reduce radiation exposure need to be implemented to maximize patient safety. There is a clear need for physicians ordering, performing and interpreting the tests to understand the issues regarding value-based imaging and to optimally implement this understanding. We meet these educational needs through a live activity entitled: Advances in Nuclear Cardiology, Cardiac CT and Cardiac MRI: 38th Annual Case Review with the Experts. The course is designed to meet the current needs of professionals who perform or request nuclear cardiology or cardiac CT. The course covers the use of these modalities across the spectrum of patients routinely seen by cardiologists in typical day-to-day practice and is designed to improve ordering patterns and increase quality in performing, interpreting, reporting and applying the advanced imaging methods. A unique feature of the program is the extensive use case presentations of each subject as a proven effective teaching tool. It also includes multiple sessions with group faculty discussions. There is a focus on incorporating new guidelines in practice and the latest evidence from clinical trials and registry findings

1. Identify up to date evidence regarding the information provided by tests, the appropriate use of testing an how the tests affect outcomes an costs in coronary and noncoronary heart and aortic disease
2. Recognize the implications of 2019 ESC CTA ACCAHA chest pain guidelines on the use of noninvasive testing
3. Implement the latest acquisition processing protocols, instrumentation and software for multiple imaging modalities
4. Explain how new approaches to functional assessmentsuch as coronary flow reserve, noninvasive fractional flow reserve, and plaque measurementsenhance the information obtained from testing.
5. Improve image interpretation and recognition of image artifacts
6. Recognize strategies tor educe patient radiation and contrast exposure while conduct high quality studies
7. Apply optimal protocols for pharmacologic stress testing
8. Create optimal reports that integrate test findings and provide guidance for patient management
9. Identify the latest information regarding how test findings should be used to guide patient management decision
10. Use criteria and evidence based strategies to reduce inappropriate testing
11. Identify knowledge gaps regarding blueprints for the CBNC and CBCCT Boards

Topics :

1. AI in Cardiac CTA- Quantification of Coronary Plaque- Prediction of Risk-Prediction, and Ischemia

2. Amyloid Quantitation- Decreasing Subjectivity in PYP Interpretation

3. Amyloid Specific PET Tracers

4. Beyond Perfusion with MPI- AI Analysis of CAC, Chamber Volumes, Epicardial Fat, Body Composition and Beyond

5. Beyond the Images- The Essential Role of Excercise and Functional Assessment in Cardiac Testing

6. Cardiac MRI and PET in Microvascular Disease

7. Cardiac MRI in Sarcoidosis and Other Inflammatory Cardiomyopathies

8. Case Review- CTA in Valvular Disease

9. Case-Based Interpretation of Flurpiridaz MPI

10. Central Role of Cardiac CT in Structural Heart Disease

11. Changing the Outlook in Cardiac Amyloidosis- Current and Novel Therapies

12. Choosing Between Flurpiridaz and Rubidium

13. Class IA Guideline Recommendation for Chest Pain- What Evidence Brought Coronary CTA Here

14. Clinical Value of Myocardial Blood Flow Measurement

15. Combining Anatomy and Physiology with SPECT and PET. Crucial Role of CAC Scanning in Patients

16. Coronary Artery Calcium (CAC) Scanning- Central Role in Preventive Cardiology

17. Coronary CT in Mitral Valve and Afib- Watchman and TMVR

18. Coronary CTA and FFRct for the Interventionalist- Use in Planning and Guiding PCI

19. Coronary CTA in Asymptomatic Patients

20. Coronary CTA in Evaluation of Patients with Known CAD (Stents, CABG)

21. Coronary CTA in Evaluation of Suspected CAD in Daily Practice

22. Coronary CTA- Special Consideration for Women

23. Debate- Coronary CTA Will Replace Stress Testing

24. Evolving Trends in CAD- Shifting Risk Factors, Symptoms, and Mortality Drivers

25. FDG PET in Sarcoidosis- Practical Considerations

26. Flurpiridaz- The Ideal PET Perfusion Tracer

27. Game-Show Jeopardy- Cardiac CT, Nuclear, and CMR

28. How to Integrate Stress Myocardial Blood Flow and Flow Reserve in Clinical Reporting and Guiding Therapy

29. How to Start Using Flurpiridaz- Lab Preparation, Protocols, Exercise vs Pharmacologic Stress

30. Incorporating Artificial Intelligence in Interpreting Reports of SPECT MPI- Case Interpretations

31. Integrating Visual and Quantitative Analyses of SPECT and PET- Improving Your Scan Interpretation- Case Illustrations

32. Ischeia Evaluation with Coronary CTA- FFRct

33. MBF-MFR with Cardiac MRI- Becoming Routine in Stress MRI

34. MBF-MFR with PET- How to Perform Quality Control, Interpret and Report

35. MFR with SPECT- Ready for Prime Time-

36. MRI in Cardiac Amyloidosis- Strengths and Limitations

37. My Best Teaching Cases

38. Myocardial Bridging and Coronary Anomalies on Coronary CTA- When is Further Assessement Needed and What Should It Be

39. Myocardial Viability- CMR and FDG PET

40. Nuclear Cardiology in 2026 and Beyond

41. Perfusion and Blood Flow Quantitation- Transmural and Subendocardial

42. PET or SPECT- Right Test for the Right Patient

43. Pharmacologic Stress- Combined with Exercise or Alone- What You Need to Know

44. Plaque Imaging in Guiding Patient Management

45. Problems fo Coronary CTA- Small Stents, CAC, Breathing

46. Putting it All Together- Value-Based Use of Cardiac Imaging

47. Quantitation in Sarcoidosis Interpretation

48. Quantitative Plaque Analysis in Tracking Progression of Disease

49. Stress First SPECT Protocols- Improved Defect Detection, Stress Only Procedures

50. Tc-99m Pyrophosphate (PYP) Imaging- Acquisition, Processing, Interpretation PET-based Radiotracers

51. The Disease, the Suspicion-Diagnostic Pathways, and Treatments

52. The Future of Cardiac CT- Photon Counting CT and More